Abstract
BackgroundKabuki syndrome (KS) is a clinically recognisable syndrome in which 70% of patients have a pathogenic variant in KMT2D or KDM6A. Understanding the function of these genes opens the door...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have